Phase 1 proof-of-concept clinical trial of KP-415 for the treatment of attention deficit hyperactivity disorder.

Trial Profile

Phase 1 proof-of-concept clinical trial of KP-415 for the treatment of attention deficit hyperactivity disorder.

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs KP-415 (Primary) ; Methylphenidate
  • Indications Attention-deficit hyperactivity disorder
  • Focus Adverse reactions; First in man; Pharmacokinetics; Proof of concept
  • Most Recent Events

    • 28 Jun 2017 KemPharm held an EOP1 meeting with the FDA to discuss the data from this trial, as reported in a media release.
    • 14 Dec 2016 Preliminary results published in the KemPharm Media Release.
    • 14 Dec 2016 Status changed from recruiting to completed, according to a KemPharm media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top